Dach Daily™

Home NewsDACHGermany The privileged status of orphan medicines in Germany

The privileged status of orphan medicines in Germany

by admin


In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers. Similarly, Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) recently published its analysis regarding the price impact on orphan drugs after an abridged assessment and subsequent full benefit. GlobalData has therefore taken the opportunity to assess the current situation of orphan drugs in the German oncology market. To gain…



Source link

You may also like

About Us

Dach Daily™ aggregates, publishes and distributes news to media in the DACH region (Germany (D), Austria (A) and Switzerland (CH). Dach Daily™, in association with EuropeNewswire.net™, not only provides press release distribution to news outlets in the DACH region, but the newswire service also reaches media in the entire Europe.

Recent News

Dach Daily™ is part of GroupWeb Media Network. © 2024 GroupWeb Media LLC